| Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors (NCT02923466) | Vyriad, Inc. | 2017-04-17 |
| Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors (NCT02857920) | Fuda Cancer Hospital, Guangzhou | 2016-08-01 |
| Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors (NCT02853903) | Fuda Cancer Hospital, Guangzhou | 2016-07-01 |
| Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors (NCT02843204) | Fuda Cancer Hospital, Guangzhou | 2016-07-01 |
| Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation (NCT02786628) | UNC Lineberger Comprehensive Cancer Center | 2016-02-01 |
| A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours (NCT01721148) | ASLAN Pharmaceuticals | 2012-10-01 |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach (NCT01611857) | SCRI Development Innovations, LLC | 2012-07-01 |
| ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers (NCT01598129) | Targovax Oy | 2012-04-01 |
| Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (NCT01554371) | University of California, San Francisco | 2012-03-27 |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (NCT01618136) | Eisai Limited | 2012-01-01 |
| Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (NCT01376505) | Robert Wesolowski | 2011-06-21 |
| Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors (NCT01286896) | The Netherlands Cancer Institute | 2011-04-11 |
| Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors (NCT01343498) | SCRI Development Innovations, LLC | 2011-04-01 |
| Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors (NCT01337505) | ImmunityBio, Inc. | 2011-04-01 |
| Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors (NCT01184807) | Otsuka Beijing Research Institute | 2009-12-01 |
| Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (NCT01023737) | The University of Texas Health Science Center at San Antonio | 2009-11-01 |
| A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (NCT00969410) | AVEO Pharmaceuticals, Inc. | 2009-08-01 |
| Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer (NCT00801151) | Institut Claudius Regaud | 2009-01-01 |
| Phase I Study of Vorinostat and Sorafenib in Advanced Cancer (NCT00635791) | University of Colorado, Denver | 2008-03-01 |
| Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors (NCT00551096) | University of Colorado, Denver | 2007-10-01 |
| Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies (NCT00388427) | University of Pittsburgh | 2007-06-01 |
| BN80927 in Patients With Advanced Malignant Solid Tumors (NCT01435096) | Ipsen | 2004-11-01 |
| To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours (NCT01951846) | Boehringer Ingelheim | 2002-11-01 |
| Long-Term Compassionate Use Study for Continued Administration of SCB01A-01 (NCT01151930) | SynCore Biotechnology Co., Ltd. | |